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Abstract
Background: Subjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer’s
disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with increased
risk for AD, as proposed in the SCD-plus criteria. We developed a structured interview (SCD-I) for the assessment of
these features and tested their relationship with AD biomarkers.
Methods: We analyzed data of 205 cognitively normal participants of the DELCODE study (mean age = 68.9 years; 52%
female) with available CSF AD biomarkers (Aß-42, p-Tau181, Aß-42/Tau ratio, total Tau). For each of five cognitive
domains (including memory, language, attention, planning, others), a study physician asked participants about the
following SCD-plus features: the presence of subjective decline, associated worries, onset of SCD, feeling of worse
performance than others of the same age group, and informant confirmation. We compared AD biomarkers of
subjects endorsing each of these questions with those who did not, controlling for age. SCD was also quantified by
two summary scores: the number of fulfilled SCD-plus features, and the number of domains with experienced decline.
Covariate-adjusted linear regression analyses were used to test whether these SCD scores predicted abnormality in AD
biomarkers.
Results: Lower Aß-42 levels were associated with a reported decline in memory and language abilities, and with the
following SCD-plus features: onset of subjective decline within 5 years, confirmation of cognitive decline by an informant,
and decline-related worries. Furthermore, both quantitative SCD scores were associated with lower Aß42 and lower
Aß42/Tau ratio, but not with total Tau or p-Tau181.
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Conclusions: Findings support the usefulness of a criterion-based interview approach to assess and quantify SCD in
the context of AD and validate the current SCD-plus features as predictors of AD pathology. While some features seem
to be more closely associated with AD biomarkers than others, aggregated scores over several SCD-plus features or
SCD domains may be the best predictors of AD pathology.
Keywords: Preclinical Alzheimer’s disease (AD), Subjective cognitive decline (SCD), Cerebrospinal fluid (CSF), Aß42,
Preclinical AD, CSF biomarkers
Background
Subjective cognitive decline (SCD), the subjective experi-
ence of worsening cognitive performance among cogni-
tively normal older individuals, can indicate an at-risk
stage of Alzheimer’s disease (AD) [1, 2]. Several studies,
using a variety of assessments, found SCD to predict ob-
jective cognitive decline [3, 4], incident mild cognitive
impairment (MCI) [5] and incident AD dementia [5, 6].
Furthermore, in several cross-sectional studies, cogni-
tive complaints were found to correlate with biomarkers
of early AD pathology such as amyloid-ß (Aß). For ex-
ample, Amariglio and colleagues [7] found an associ-
ation of Aß deposition in the brain and a memory
complaint composite score in cognitively normal older
adults. Higher baseline memory complaint scores in par-
ticipants screened positive for Aß were also found to
predict faster cognitive decline [8].
These and other studies have established that some
form of SCD can be a clinical indicator of early AD (stage
2, according to the NIA-AA research framework [9]).
Based on the evidence accrued until 2014, a group of
researchers forming the SCD-Initiative proposed the
“SCD-plus criteria” as an enrichment strategy for the
likelihood of preclinical AD in individuals with SCD [9],
comprising (a) Subjective decline in memory rather than
other domains, (b) onset of SCD within the last 5 years,
(c) age of onset ≥ 60 years, (d) particular concerns associ-
ated with SCD, (e) the feeling of worse performance than
others of the same age group, (f ) confirmation of per-
ceived cognitive decline by an informant, and (g) the
presence of the APOE e4 genotype.
These criteria were not meant to be final but were con-
sidered to be in need of further refinement and validation
in research studies. For example, recent studies suggest
that consistency of complaints over time may be another
feature associated with the presence of AD risk [6].
Current assessments differ widely regarding administra-
tion (interview with a physician versus questionnaire),
content, number of items, and scaling, leading to a large
variety of methods [10, 11]. While some SCD studies used
single questionnaire items [12] or items from different
SCD questionnaires [13–15], others were using one out of
many questionnaires [7, 11] or even composites derived
from several questionnaires (e.g., [16]). Psychometric ana-
lyses are ongoing to extract from existing data those single
SCD questions or features contributing most to the pre-
diction of AD [17].
One potential limitation of most current SCD assess-
ments is that they only refer to memory [11]. Subjective
memory concerns are highly prevalent in older adults
(e.g., around 53% in a large population-based sample
[18]) and may therefore be highly sensitive but of insuffi-
cient specificity regarding the detection of preclinical
AD. Thus, current research suggests involving additional
cognitive domains in SCD assessment [2], e.g., subjective
complaints in executive function which have also been
associated with Aß deposition in cognitively normal in-
dividuals [7]. Irrespective of the cognitive domains, stud-
ies have also highlighted specific features of SCD which
are associated with AD biomarkers, objective cognitive
decline, or incident MCI. Perrotin and colleagues [19]
for example found an association between the compari-
son of memory function to peers with Aß deposition
using Pittsburgh compound B positron emission tomog-
raphy (PiB-PET) imaging.
Another feature replicated in several studies is the
presence of worries associated with the subjective wors-
ening in function.
A recent study on the validity of SCD-plus criteria in
cognitively unimpaired patients of the Amsterdam mem-
ory clinic [20] could not find significant relationships be-
tween amyloid biomarkers and any of the examined
subjective cognition features (“memory specific decline”,
“onset of complaints within 5 years”, “worse performance
than others of the same age”, and “informant reports de-
cline”). Amyloid was only predicted by higher age (> 60)
and ApoE4 in this study, in line with established know-
ledge [21]. Apart from sample size limitations in this
study, the apparent insensitivity of the subjective cognition
features in the SCD-plus criteria could have been due to
the relatively young age of the memory clinic subjects (64
years on average) and to the measurement of SCD with
two different questionnaires which were not designed to
fully capture the SCD-plus criteria.
Importantly, there is no straightforward, interview-
based assessment of SCD criteria, and a single validation
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study of SCD-plus features is still missing. In clinical set-
tings, structured interviews offer an advantage over
questionnaires as they rely on personal contact to the
patient, thus improving acceptance, and may allow an
informed clinical rating of participants’ complaints ac-
cording to diagnostic categories. They are an established
strategy for reducing information variance [22, 23].
In the present study, we aimed to provide further valid-
ation of the SCD-plus features while also testing the use-
fulness of an interview-based assessment for AD-related
SCD. We developed a new, semi-structured interview for
detailed SCD assessment (SCD-I) which includes assess-
ment of perceived decline in different cognitive domains
as well as the SCD-plus criteria mentioned above. We ex-
amined cognitive complaints as measured by the SCD-I in
a sample of cognitively normal older adults and tested for
associations of individual SCD features as well as compos-




The DZNE-Longitudinal Cognitive Impairment and De-
mentia Study (DELCODE) is an observational longitudinal
memory clinic-based multicenter study in Germany with
the aim to improve characterization of the early, preclin-
ical stage of AD with a focus on SCD patients. The study
protocol was approved by Institutional Review Boards of
all participating study centers of the DZNE [24]. All pa-
tients provided written informed consent.
Participants
We included 205 participants (age M = 68.9; SD = 5.4)
from an interim data release of the DELCODE study.
Here, we analyzed only data from cognitively normal in-
dividuals. These included healthy controls (HC, n = 76)
who all had denied any worrisome subjective cognitive
impairment during an initial telephone screening for
study eligibility, first-degree relatives of patients with AD
dementia (AD relatives, n = 24), and memory clinic pa-
tients with unimpaired test performance but with a re-
port of worrisome subjective cognitive decline at the
initial screening (SCD patients, n = 105).
The diagnostic criteria for group definition and the
study protocol have been described in detail previously
[24]. The HC and the AD relatives group were both re-
cruited via local newspaper advertisement and con-
ducted a telephone interview to screen for suitability.
The SCD patient group was recruited via the memory
clinics of all participating DELCODE sites. These indi-
viduals sought diagnostic evaluation of subjectively expe-
rienced a decline in cognitive functioning. It was
required that they expressed concerns to the physician
of the memory clinic regarding their self-perceived cog-
nitive decline while their test performance was above −
1.5 SD of age-, sex-, and education-adjusted normal per-
formance on all subtests of the CERAD neuropsycho-
logical assessment battery. Subsequent to these different
screening procedures, subjects in all groups were en-
rolled into the DELCODE study and underwent a uni-
form baseline assessment including the semi-structured
SCD interview described below.
Subjective cognitive decline interview (SCD-I) and scoring
procedures
The SCD-I allows assessment of subjective cognitive de-
cline in five different cognitive domains (memory, lan-
guage, planning, attention, any other cognitive decline) and
comprises all five SCD-plus features which refer to sub-
jective experience [2]. All interviews were administered
face to face by trained study physicians and lasted ap-
proximately 5 min. The interview consists of 3 parts in-
cluding an open question at the beginning as well as a
structured part for the participant and the informant. In
this study, we are only focusing on the structured part.
The whole interview procedure is shown in Add-
itional file 1. For each domain, the physician asked the pa-
tient if he/she had noticed any worsening in function (e.g.,
“do you feel like your memory has become worse”). If the
participant answered this question with yes, the physician
added more in-depth questions about the domain to as-
sess the presence/absence of SCD-plus features, i.e., spe-
cific questions about associated worries (“Does this worry
you?”), onset (“How long ago did you start to notice the
decline?”), and the performance in comparison to peers
(“Compared to other people of your age, would you say
that your performance is worse?”). Furthermore, partici-
pants were asked whether they had talked to a physician
about their subjective cognitive decline (this information
was not analyzed in the present study as by design all
SCD subjects had been referred to a memory clinic). In
addition, a modified SCD-I was administered to a study
partner (usually a relative or spouse) of all participants,
asking for an observed decline in any of the same five do-
mains. Study partners were not asked the in-depth SCD-
plus questions but were also asked about whether they
had observed any behavioral changes in the participant
(this was not analyzed in the present study).
The quantification of response data allows derivation
of the total number of domains with a reported decline
as well as the total number of fulfilled SCD-plus fea-
tures. This scoring was executed as follows:
Number of fulfilled SCD-plus features: Reported as
number of fulfilled SCD-plus features ranging from 0 to 5
(decline in memory, onset within the last 5 years, worries
associated with a decline in a cognitive domain, feeling of
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worse performance than others of the same age group, con-
firmation of perceived cognitive decline by an informant).
Number of reported SCD domains: Sum of the number
of cognitive domains (memory, language, planning, at-
tention, others) in which the participant endorses a
worsening in function (maximum score = 5).
Neuropsychological and clinical assessment
The DELCODE test battery included an extensive neuro-
psychological and clinical assessment which covers tests
for global cognitive function and different cognitive do-
mains (described in detail previously [24]) as well as a
structured medical history and a standardized physical
examination [24]. Here, we focus on the assessment rele-
vant to the present study. The Mini-Mental State Examin-
ation (MMSE) is used to describe the global cognitive
function in all subgroups, and the 15-item short form of
the Geriatric Depression Scale (GDS) to measure and con-
trol for depressive symptomatology. In a previous memory
clinic study [25], we had found that questions on SCD
(different from those in the SCD-I) were associated with
CSF AD biomarkers, and this was still true after control-
ling for delayed recall memory performance (an estab-
lished, strong predictor of CSF AD biomarkers [26]). We
analyzed the present data in the same manner with the
ADAS delayed recall as covariate.
CSF AD biomarker measures
CSF samples were collected according to previously de-
scribed standard operating procedure [24] by using
commercially available kits according to vendor specifi-
cations (V-PLEX Aβ Peptide Panel 1 (6E10) Kit (Intra
Plate variance of 3.0 and inter plate variance of 8.8),
K15200E and V-PLEX Human Total Tau Kit (intra plate
variance of 4.5 and an inter plate variance of 17.1),
K151LAE (Mesoscale Diagnostics LLC, Rockville, USA),
and Innotest Phospho-Tau (181P) (intra plate variance of
1.7 and inter plate variance of 11.4), 81581, Fujirebio
Germany GmbH, Hannover, Germany).
We used the continuous variables of Aß-42 level, the
p-tau-181, and the total Tau level as outcomes. In
addition, we calculated a CSF amyloid/tau ratio score
(Aβ42/(240 + 1.18 × tau) which has been established as a
specific marker for AD [27]. We decided to use continu-
ous biomarker values (rather than categorical variables
based on cutoffs) in order to explore associations of SCD
within the complete spectrum of AD pathological change,
especially Aβ accumulation, in cognitively normal individ-
uals, i.e. without loss of information due to dichotomiza-
tion. This is supported by recent study results, which
showed that Aβ accumulation, in cognitively normal older
participants still classified as Aß-negative, was associated
with longitudinal changes in memory function [28].
Statistical analysis
All analyses were performed using SPSS Version 23.0
(IBM) for Windows. For descriptive statistics, we used x2
test for categorical and analyses of variance for continuous
variables as well as post hoc t tests or chi-square tests for
single contrasts. Group differences in CSF level were re-
ported as age-adjusted results based on ANCOVA. Linear
regression models were used to examine the relationship
between different SCD score and the CSF biomarker out-
come variables described above. We performed separate
analyses for the number of fulfilled SCD-plus features as
well as for the number of reported SCD domains. In step
1, we entered one of the SCD scores as a single predictor.
In a second step, we adjusted for age, sex, and education.
In order to gauge the “added benefit” of SCD questions
over and above memory testing, we controlled for objective
memory performance by using the world list delayed recall
score as a covariate. All cases with missing data in any vari-
ables were excluded. Since we included just participants
with CSF biomarkers, we tested whether our sample dif-
fered significantly from cognitively normal DELCODE par-
ticipants without biomarkers (n = 291). The samples did
not differ in terms of age (t(493) = − 1.84; p = .067), sex
(X2 = .441; p = .507), and education (t(491) = − .304;
p = .761) and neither regarding the number of fulfilled
SCD plus features (t(493) = − .288; p = .774) or the number
of reported SCD domains (t(493) = .969; p = .333).
Results
Sample descriptive statistics and group differences in
demographic, clinical, cognitive, and biomarker data
The 205 included participants (of whom 107 (52.2%) were
female) had a mean age of 69 years (SD = 5.4) and mean
education of 14.7 years (SD= 2.95). Demographic, neuro-
psychological, and clinical characteristics of the sample as
well as detailed group differences are shown in Table 1. HC,
AD relatives, and SCD patients did not differ with regard to
sex, education, MMSE, and word list delayed recall score,
although we note SCD patients and AD relatives had
slightly worse memory performance. AD relatives were
younger than SCD patients and HC, while SCD patients
had slightly higher scores in the GDS, which however where
in the normal range (GDS < 6) in most cases (97.3%).
The three groups differed significantly in the CSF-Aß42
level and the Aß42/Tau ratio (see Table 1) after adjusting
for age. The SCD group had a significantly lower Aß-42
concentration and a significantly lower Aß42/tau ratio rela-
tive to the HC group. There was no significant group dif-
ference in p-tau-181 level and in t-tau level (see Table 1).
Prevalence and group differences of SCD-plus features
and SCD domains
An overview of the prevalence and the group differences
in SCD-plus features is given in Table 2. Reported
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domains in the total sample are shown in Fig. 1. Out of
the 205 individuals, 76.1% reported a cognitive decline
in at least one domain, and among those experiencing a
decline, 72% also endorsed worries associated with the
decline. Most complaints were reported in the memory
(n = 129; 62.9%) and language domain (n = 127; 62%).
As expected, due to the inclusion criteria, the three
participant groups differed in the endorsement of decline
in SCD domains and SCD-plus features (see Table 2). Un-
surprisingly, most (93.3%) SCD patients reported a decline
in memory, but a sizeable proportion of the other partici-
pants also did, although less frequently (HC 26.3%; com-
parison with SCD, X2 = 87.26; p < .001; AD relatives 45.8%;
comparison with SCD X2 = 33.65; p < .001). The same pat-
tern was observed for experienced decline in language
abilities (SCD = 82.9%, HC = 36.8%, pairwise comparison
X2 = 40.29; p < .001; AD relatives = 50%, pairwise compari-
son to SCD X2 = 11.82; p < .001).
The number of domains with a reported decline differed
significantly across the groups (F(2,202) = 70.17, p < .001).
On average, the SCD group mentioned a decline in two
domains, while the number of impaired domains was 0.8
in the healthy control group (p (bonf. adj.) ≤ .001) and 1.5 in
the AD relatives’ group (p (bonf. adj.) ≤ .001).
Group differences also emerged regarding the reported
onset of decline in participants reporting any such decline.
Around 80% of SCD patients reported an onset of cogni-
tive worsening (in any domain) within the last 5 years. This
was significantly more often than in the HC group (44.5%;
X2 = 44.87; p < .001) and in the AD relatives (45.8%; X2 =
12.66; p < .001), who more often reported a more distant
onset of decline. There was no significant difference be-
tween HC and AD relatives (X2 = 1.63; p = .20).
The feeling of worse performance than others (in any
domain) was also most frequently reported in the SCD
group (29.5%) compared to healthy controls (1.3%)
(X2 = 24.10; p < .001) and relatives of AD patients (12.5%;
X2 = 2.92; p = .088). AD relatives also reported this
slightly more often than HC (X2 = 5.94; p = .042).
Interestingly, although all HC participants had negated
a worrisome cognitive decline during the initial telephone
screening, a worrisome decline (in any domain) was re-
ported by 14.5% of HC during the physician-led personal
interview. In AD-relatives, where the absence of
worrisome cognitive decline was not an exclusion criter-
ion, the prevalence was 29.2%. As expected because of the
inclusion criteria, SCD patients reported concerns much
more frequently (90.5%) compared to both at-risk groups
(SCD vs. HC: X2 = 104.58; p < .001; SCD vs. AD relatives:
X2 = 44.37; p < .001), which did not differ from each other.
The informant also reported (i.e., confirmed) a decline
in at least one domain for the majority (57.8%) of the
SCD patients who reported a decline by themselves in at
least one domain, while such a confirmation occurred
less often in the HC group (39.5%, X2 = 24.24; p < .001)
and in AD relatives (43.8%, X2 = 5.710; p < .05).
The number of fulfilled SCD-plus features differed highly
significantly between the three groups (F(2,202) = 99.807;
p < .001). Participants in the SCD group fulfilled more
SCD-plus features (M = 3.5) than participants in the HC
group (M = 0.93, p (bonf. adj.) ≤ .001) and in the AD relatives
(M= 1.63, p (bonf. adj.) ≤ .001), which also differed from each
other (p (bonf. adj.) ≤ .05).
Relationship between AD biomarkers and SCD plus
features and SCD domains
In the combined sample of all three groups, lower age-
adjusted CSF-Aß-42 levels were found in those fulfilling





















Memory Language Attention Other Planning
%
SCD-I Domains
reported decline per domain
reported worrisome decline per domain
Fig. 1 Frequency of domains reported with an experienced decline and associated worries, respectively
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202) = 7.65, p < .01, η2p = .036), onset within the last 5
years (F(1,202) = 6.07, p < .05, η2p = .029), and the con-
firmation by an informant (F(1,202) = 4.19, p < .05, η2p
= .032, Table 3). The association of lower CSF-Aß-42
with worries in any domain approached significance
(F(1,202) = 3.68, p = .056, η2p = .018).
Hierarchical linear regression analysis showed that the
number of fulfilled SCD-plus features was a significant
predictor of a reduced (more pathological) CSF-Aß-42
level (ß = − .225, p < .005) (Fig. 2) and of a reduced (more
pathological) CSF Aß-42/tau-ratio (ß = − .189, p < .01) in-
dependent of age, sex, and education. In contrast, the re-
lationship between the number of fulfilled SCD-plus
features and CSF total Tau (ß = − .055, p > .05) and p-
tau-181 (ß = − .077, p > .05) was not significant.
Using objective memory performance (word list de-
layed recall) as an additional covariate to control for
subtle group deficits in cognition, we found that the
SCD-plus score was still a significant predictor, explain-
ing more variance than objective memory performance
(as seen by the contribution to R2 in the prediction
model) in CSF-Aß42 and CSF Aß-42/tau ratio (Table 4).
We further observed that participants endorsing a de-
cline in memory or language had significantly lower age-
adjusted Aß-42 levels than those who did not report a
decline in these domains (Table 3). Interestingly, a re-
ported decline in the other domains (which occurred
less often than a reported decline in memory and lan-
guage) was not significantly associated with Aß-42.
The number of reported domains with experienced de-
cline was also a significant predictor of lower CSF-Aß42
level (ß = − .209, p < .01) and lower CSF Aß42/tau-ratio
(ß = − .146, p < .05) after including age, sex, education,
and the delayed recall score to the model. For CSF-p-
tau18 and total Tau, only age (total Tau ß = .260,
p < .001; p-tau: ß = .215, p < .01) and delayed recall score
Table 3 Associations between endorsement of SCD-plus features and SCD-I domains with CSF-Aß-42 level
N = 205 CSF-Aß-42 level (pg/ml) pa
M (SD) F η2p
SCD-plus features
Decline in memory Yes n = 129 720 − 316 7.65** .036 .006
No n = 76 849 − 293
Onset of SCD within the last 5 years Yes n = 120 722 − 312 6.07* .029 .015
No n = 85 833 − 306
Particular concerns/worries Yes n = 113 727 − 309 3.68 .018 .056
No n = 92 819 − 313
The feeling of worse performance than others Yes n = 35 695 − 308 2.488 .012 .116
No n = 170 783 − 313
Confirmation by an informant Yes n = 81 695 − 315 4.19* .032 .017
No n = 124 816 − 304
SCD-I domains
Decline in memory Yes n = 129 720 − 316 7.65** .036 .006
No n = 76 849 − 293
Decline in language Yes n = 127 727 − 312 5.18* .025 .024
No n = 78 835 − 306
Decline in attention Yes n = 62 738 − 349 .751 .004 .387
No n = 143 781 − 297
Decline in planning Yes n = 26 704 − 326 1.049 .005 .307
No n = 179 777 − 312
Decline in other Yes n = 48 716 − 302 1.65 .008 .201
No n = 156 780 − 313




aAdjusted for age for the SCD-I domains and for age and education for the SCD-plus features, η2p > .01 = small effect; η
2
p > .06 = average effect; η
2
p > .14 = large
effect (according to Cohen 1988)
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(total tau: ß = − .167, p < .05; p-tau: ß = − .151, p < .05)
were significant predictors (Table 4, Fig. 3).
Discussion
In the present study, we demonstrate the feasibility and
validity of a short semi-structured interview (SCD-I) de-
signed to capture important aspects of SCD in the con-
text of preclinical AD. In particular, the SCD-I captures
all current experiential SCD-plus criteria within a single
instrument. We here used the SCD-I to explore the
quantitative and qualitative diversity of subjective cogni-
tive decline in cognitively normal subjects at clinical or
familial risk for AD, and in cognitively normal controls
screened for the absence of either risk. We also estab-
lished the association of SCD-plus items and of two
quantitative SCD-I scores with CSF biomarkers.
Prevalence of SCD domains and SCD-plus features
Across all three groups of these cognitively normal older
adults, memory and language complaints were most fre-
quent while complaints in the domain planning were rela-
tively rare with only 10% of participants reporting them.
As expected, due to the inclusion criteria, almost all SCD
patients reported a decline in one or more cognitive do-
mains within the last years. However, two thirds of the
AD relatives and about half of the HC group also
endorsed at least some cognitive decline. The latter is in
line with community studies reporting prevalence rates
from 25 to 50% of memory complaints increasing with
age [29]. This indicates that SCD can be caused by other
non-AD etiologies including personality traits [30],
physiological aging, or the research setting [31], highlight-
ing the need to further investigate the features characteriz-
ing SCD in the context of preclinical AD.
A worrisome cognitive decline was reported by most of
the SCD subjects, again, an expected finding given that a
worrisome decline reported during the memory clinic
screening was required for inclusion. Interestingly, 29.2%
of the AD relatives and even 14.5% of the HC group re-
ported at least one worrisome cognitive decline during
the baseline SCD interview. The latter finding was con-
trary to our expectations since these “control” individ-
uals had negated a question regarding any worrisome
self-perceived cognitive decline during the initial tele-
phone screening. Yet, they expressed some concern to
the clinician during the SCD interview. In contrast, 10%
of the SCD patient group did not report worries in the
SCD-I although expression of concerns regarding the
self-perceived cognitive decline to the physician of the
memory clinic at screening was a mandatory inclusion
criterion. These discrepancies may be due to several rea-
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R² linear= .001
Fig. 2 Relationship between CSF biomarkers and the number of fulfilled SCD-plus features in cognitively normal individuals (n = 205)
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and subjective reports in general, the difference between
settings, and possibly an undeclared interest of some
healthy volunteers to participate in a study which they
imagine to confer some health benefit [32]. Consistency
of worries over time has been shown to relate to clinical
progression [6] and thus will be an interesting issue for
future analyses of longitudinal SCD-I data.
Most SCD participants (81%) reported an onset of a de-
cline within the last 5 years. This is perfectly in line with
the reported onset in the SCIENCE SCD-cohort, where
83% reported an onset within the last 5 years [33]. Inter-
estingly, those HC and AD relatives who reported any de-
cline frequently indicated a more distant onset. This
suggests a different pattern of perceived onset of decline
in cognitively unimpaired memory clinic patients.
The SCD-plus feature performing subjectively worse
than others was reported least frequently, endorsed by
30% of the SCD patients but only by 1% in the healthy
control. Finally, the confirmation of any complaints by an
informant occurred for the majority of SCD participants
(58%). Interestingly, 38% of informants of those controls
who reported any decline also confirmed an observed de-
cline in at least one domain, as did 44% of the informants
of AD relatives endorsing any cognitive decline. Thus,
there is a considerable overlap between groups not only
regarding any self-reported decline, but also regarding the
degree of confirmation by the informants.
Relation of SCD-I items and SCD-I scores with AD CSF
biomarkers
In line with the first interim report from the DELCODE
study based on a smaller sample [28], we found that SCD
participants had lower age-adjusted CSF-Aß42 levels and
lower CSF-Aß42/Tau ratios than HC, while the total Tau
level and the p-Tau-181 level did not differ between groups.
The SCD-plus sum score and the SCD-I domain score
were significantly and specifically associated with mea-
sures of amyloid pathology, and to the same extent with a
derived amyloid/Tau ratio, but not with p-Tau181 or t-tau
level alone. The associations with amyloid are in line with
previous studies using either CSF amyloid measures [14,
25] or amyloid PET [16, 34]. Like in the present study,
CSF-Tau was not associated with quantitative SCD in the
studies of [14, 25]. However, significantly positive associa-
tions between quantitative SCD and regional Tau mea-
sured with flortaucipir PET have been reported [16, 35].
This discrepancy may be due to the low correlation be-
tween CSF Tau and flortaucipir tracer uptake in early dis-
ease stages [36].
Three of the suggested SCD-plus features were signifi-
cantly associated with amyloid pathology: experienced
decline in memory, onset of subjective decline within the
last 5 years, and confirmation by an informant. The as-
sociation with worries was almost significant (p = .056),
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Fig. 3 Relationship between CSF-biomarkers and the number of fulfilled SCD domains in cognitively normal individuals (n = 205)
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cognitively normal memory clinic patients [33] and a
community-based study [20, 37] also reported an associ-
ation of worries with amyloid pathology. To our know-
ledge, only the Amsterdam SCIENCe cohort has tested
associations of all SCD-plus criteria with amyloid path-
ology, using different questionnaires plus some questions
similar to those of the SCD-I interview to reflect the cri-
teria. Two studies from this cohort [20, 33], in contrast
to our own study, did not find associations with “decline
in memory” and “onset within 5 years”. Apart from dif-
ferences in assessment, this may be due to the younger
age of the SCIENCe cohort as compared to the DEL-
CODE cohort (64 versus 69 years on average). However,
an association of subjective memory decline (e.g., [7])
and cognitive ratings by informants [38] with amyloid
pathology has been found before. Our study appears to
be the first one directly testing and validating the SCD-
plus criterion “onset within the last 5 years”.
The biomarker associations of the single SCD domains
revealed that perceived decline in the memory and lan-
guage domain showed the highest associations with AD
biomarkers, which is in line with studies suggesting that
memory complaints are the best predictor of incident
MCI [37] or that memory-related complaints are associ-
ated with PIB retention in healthy older adults [7]. How-
ever, to our knowledge, this is the first study reporting
an association of Aß42 with subjectively experienced de-
cline in the domain of language abilities. This pattern is
consistent with the earliest neuropsychological deficits
in AD starting with decline in episodic memory followed
by deficits in language [39].
We also observed a relationship between objective
memory performance and CSF-Aß42 level irrespective
of the subjective complaints. While subtle objective cog-
nitive decline can be expected in “late” preclinical AD
[40], we showed that subjective cognitive decline is
equally and independently predictive of amyloid abnor-
mality in cognitively normal individuals. This extends
findings of a previous study which also found an inde-
pendent association of subjective and objective cognitive
performance with CSF-Aß in patients with MCI [25].
Strengths and limitations
The current brief SCD interview has been derived from
the assessment routine in memory clinics and standardizes
the assessment of those SCD features which are currently
considered relevant for assessing suspected preclinical and
prodromal AD. Aside from establishing the presence or ab-
sence of each of these features, it offers summary measures
of quantitative SCD, which in the current study predicted
the presence of amyloid pathology.
The SCD-I is a direct operationalization of the SCD-
plus criteria and therefore has high content validity.
While this is not the only conceivable operationalization,
it is one which is frequently used in clinical assessment,
e.g., in DSM-based interviews, like the SCID [41], or in
questionnaires directly based on diagnostic criteria (like
the PHQ-9 [42]). The SCD-I discriminated well between
the HC and SCD groups in our study. This is somewhat
circular for the items of cognitive decline and related
concerns, as these SCD-plus criteria were used for group
definition at inclusion. However, also the other SCD-plus
items assessed at baseline with the SCD-I markedly dif-
fer between the groups. Furthermore, most SCD-I items,
and both SCD-I summary scores, were associated with
CSF-amyloid, implicating that it captures, to some de-
gree, AD-related cognitive concerns. In sum, this pro-
vides a first validation of the SCD-I as a measure for
SCD. This does not imply that this assessment method
is superior to others, e.g., questionnaire-based methods.
For example, the SCD-Q [43] captures many of the
SCD-plus items (it lacks the question of comparison
with others of the same age, and asks for perceived de-
cline in the last 2 years, rather than 5 years). In an eld-
erly population sample enriched for family history of
AD, larger SCD-Q scores were associated with objective
cognitive impairment and confirmation of decline by an
informant predicted cerebral volume reduction in AD-
related brain areas [44]. More data are needed to com-
pare the prediction of the same outcomes by different
SCD assessment methods.
One limitation of the present SCD-I is that it directly
asks for an experienced or observed decline in five neuro-
psychological domains, using global and commonly used
terms like memory, language, or planning. Whether sub-
jects “correctly” identify their specific problems as being
related to one of those domains is unknown. However,
subjects can endorse deficits in many domains as opposed
to only one or two, and the domain score, like the SCD-
plus score, seems to capture SCD severity, as it is related
to AD pathology. The SCD domain scores can be calcu-
lated for reports of patients and informants alike, so that
the difference between both scores could be used to exam-
ine the shift from a hyperawareness to hypoawareness of
cognitive deficits with the progression of AD [45].
Current research suggests that other specific aspects
or higher-order thinking, e.g., self-reports of confusion,
are also related to AD pathology in cognitively normal
individuals [15]. To identify alternative descriptions of
experienced and possibly pathological cognitive change,
we have added an open initial question in the SCD-I
asking for any observed cognitive change during recent
years. The recorded answers will be analyzed with the
help of qualitative methods [46, 47] and may give rise to
the identification of new AD-related SCD features not
captured by this first iteration of the SCD-I.
Furthermore, it should be noted that individuals in-
cluded in the present study were recruited in the
Miebach et al. Alzheimer's Research & Therapy           (2019) 11:66 Page 12 of 14
memory clinic (SCD patients) as well as from the com-
munity (HC and relatives). Evidence suggests that the
active process of seeking medical help due to self-per-
ceived cognitive decline is a factor with potential prog-
nostic value for the presence of AD pathology [12, 13].
Validation of the SCD-I in other samples will be another
research goal of the future.
Conclusion
Findings support the use of interview-based approaches
for the assessment of AD-related subjective cognitive de-
cline. In this study, detailed questions on perceived de-
cline in different cognitive domain and on the presence/
absence of the SCD-plus features were related to AD
biomarkers in cognitively normal participants of the
DELCODE study. Combining information on perceived
decline in multiple cognitive domains and SCD-plus fea-
tures is useful for prediction of underlying AD patho-
logical change in these individuals. The consistent report
of worries/non-worries is possibly an additional SCD-
plus feature to be considered in future SCD studies.
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